The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Embodiments described herein relate to novel chromatography media for removing anti-A and/or anti-B antibodies from a sample, as well as methods of using the same. The media described herein have several advantages over previously described media including, acid and alkaline stability.

Embodiments described herein relate to novel chromatography media for removing anti-A and/or anti-B antibodies from a sample, as well as methods of using the same. The media described herein have several advantages over previously described media including, acid and alkaline stability.

Described and featured herein are binding polypeptides and antibodies, and antigen binding portions thereof, that specifically bind to the HbG-Makassar variant polypeptide or peptide and methods of using such binding polypeptides and antibodies to specifically bind, detect, identify, select, and/or isolate the HbG-Makassar variant polypeptide or peptide, for example, in a biological sample.

Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an improved half-life with respect to the parent polypeptide, and including at least one mutation of the Fc fragment increasing the binding of Fc to FcRn; and at least one mutation of the Fc fragment increasing the sialylation of Fc.

Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an improved half-life with respect to the parent polypeptide, and including at least one mutation of the Fc fragment increasing the binding of Fc to FcRn; and at least one mutation of the Fc fragment increasing the sialylation of Fc.

The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.

The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.